Navigation Links
Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Date:5/16/2008

MicroRNAs as Potential Biomarkers -- for Lung Cancer Diagnosis and Identification of Tumor Origin in Patients With Cancer of Unknown Primary

(CUP) MicroRNAs Objectively Identify Cancer Types With High Sensitivity and Specificity and Could Revolutionize Diagnosis and Treatment of Cancer

Results of microRNA Signature to Identify Tissue Origin Demonstrate

Accuracy Exceeding 90% and Specificity of 99%

REHOVOT, Israel and JERSEY CITY, New Jersey, May 16 /PRNewswire-FirstCall/ -- Rosetta Genomics Ltd. (Nasdaq:ROSG), a leader in the development of microRNA-based diagnostics and therapeutics, today announced that it will present multiple posters at the upcoming ASCO annual meeting in Chicago. The company also has three publication only abstracts available on ASCO's website. The event will take place from May 30 to June 3 at the McCormick Place, Chicago, Illinois.

Presented posters:

1. "MicroRNA signature identifies tissue origin of primary and metastatic tumors"; Tuesday, June 03, 8:00AM - 12:00PM; Hall S102a, abstract # 11028.

Each year approximately 70,000 patients in the United States are diagnosed with cancer of unknown primary (CUP). Accurately identifying the origin of a metastasis can be critical in guiding treatment decisions. Rosetta Genomics' scientists have designed a classifier which assigns a primary site to a cancer sample based on the microRNA expression in the sample. The overall sensitivity of this classifier is approximately 85%, with two-thirds of the samples being classified with high-confidence, reaching accuracy exceeding 90% and specificity of 99%.

2. "Differential microRNA expression in pleural mesothelioma: Implications for early detection and prognostication"; Tuesday, June 03; 8:00AM - 12:00PM; Hall S102a; abstract # 11027. Malignant mesothelioma (MM) is an asbestos induced pleural neoplasm with a median survival (MS) of 12 months, and relatively little is known about the molecular events that lead to the development of this highly aggressive disease. Using Rosetta Genomics' unique microRNA platform, Dr. Harvey Pass, NYU School of Medicine, examines whether there are distinct mir profiles between MM and normal mesothelium, and whether mirs are associated with demographic/prognostic features in MM patients.

3. "MicroRNAs as powerful diagnostic tools for the differential diagnosis of lung tumors"; Sunday, June 01; 8:00AM - 12:00PM; Hall S A1; abstract # 11112. Lung cancer is a heterogeneous disease with many histological subtypes, further complicated by the frequent occurrence of lung metastases from various tumor origins. Therefore, determining the correct diagnosis of any lung tumor often poses a difficult diagnostic challenge that may have very significant therapeutic implications. This poster will detail the use of microRNAs for differentiating between different primary lung tumors and metastases to the lung.

4. "MicroRNA expression profile identifies origin of tumors in the liver"; Tuesday, June 03; 8:00AM - 12:00PM; Hall S102a; abstract # 11026. The distinction of liver metastasis from hepatocellular carcinoma (HCC) and determining its tissue origin is a frequent problem in oncology, especially since liver metastases, and particularly adenocarcinoma, may mimic the morphology and immunoexpression of hepatocellular carcinoma. Such distinction has significant therapeutic and prognostic implications. In the present study, Rosetta Genomics and collaborators use microRNAs as biomarkers for tissue identification to distinguish between HCC and metastatic tumors in the liver.

Publication only abstracts:

5. "MicroRNAs as specific biomarkers for distinguishin
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Columbia University Medical Center and Rosetta Genomics Announce Columbia Universitys Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica
2. Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Companys MicroRNA Technology
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
5. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
6. Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers
7. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
8. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
9. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... , June 23, 2016 , ... on Thursday, July 7, 2016 , , , , LOCATION: ... , , , , EXPERT PANELISTS:  , , , ... Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and ... The global pharmaceutical industry is witnessing an exceptional era. ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... environments  Oticon , industry leaders in ... the launch of Oticon Opn ™, the world,s ... world of possibilities for IoT devices.      ... Opn, Oticon introduces a number of ,world firsts,: ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... 2016 , ... "FCPX editors can now reveal their media with growing colorful ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Color brings the ... can now reveal the media of their split screens with growing colorful panels. , ...
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are confused ... endometriosis. These women need a treatment plan to not only alleviate symptoms and ... help for preservation of fertility and ultimately achieving a pregnancy. The specialists at ...
(Date:6/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... the Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
Breaking Medicine News(10 mins):